• XenoPort Inc., of Santa Clara, Calif., reported Phase I data testing four different oral formulations of XP23829, a fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF) and is in development for relapsing-remitting multiple sclerosis and/or psoriasis.